1. Medicines
  2. Oncology
  3. KISQALI® (ribociclib)

Dosing

Recommended dosing schedule and dose adjustments with KISQALI.

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Indication: KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1

Reference

  1. KISQALI® (ribociclib) Summary of Product Characteristics.

 

Rate this content: 
No votes yet
IE172816-1 | November 2021
Oncology
Kisqali
Medicines
Print

Related Content

×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.